Abiopharma

(90% Positive) uniQure NV (QURE) Announces Enrollment Update for option Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

(90% Positive) Energous Co (WATT) Reports Q1 2026 Financial Results

(99% Neutral) Bausch Health Companies Inc (BHC) Reports Q1 2026 Financial Results

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

(85% Positive) Onconova Therapeutics Inc. (was merged with Trawsfynydd Therapeutics, Inc. on 02/04/2024) (ONTX) Files Form 8-K

Sono-Tek Reports Fiscal Third Quarter and Nine-Month Fiscal 2026 Financial Results

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Energous Reports Preliminary Financial Results for Fiscal Year 2025, Marking a Transformational Year of Growth and Platform Expansion

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data